Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial

BACKGROUND: A Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group. METHODS: CitAD was a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Drye, Lea T., Spragg, David, Devanand, D. P., Frangakis, Constantine, Marano, Christopher, Meinert, Curtis L., Mintzer, Jacobo E., Munro, Cynthia A., Pelton, Gregory, Pollock, Bruce G., Porsteinsson, Anton P., Rabins, Peter V., Rosenberg, Paul B., Schneider, Lon S., Shade, David M., Weintraub, Daniel, Yesavage, Jerome, Lyketsos, Constantine G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051660/
https://www.ncbi.nlm.nih.gov/pubmed/24914549
http://dx.doi.org/10.1371/journal.pone.0098426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051660/
https://www.ncbi.nlm.nih.gov/pubmed/24914549
http://dx.doi.org/10.1371/journal.pone.0098426

Ejemplares similares